Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Teva Pharmaceutical Industries Limited
< Previous
1
2
3
4
5
Next >
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
August 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
August 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports Second Quarter 2022 Financial Results
July 26, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
July 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Appointment of New Global R&D and Chief Medical Officer
July 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
June 29, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
June 08, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
May 25, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
May 23, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
May 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
May 10, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports First Quarter 2022 Financial Results
May 03, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
May 02, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
April 19, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
April 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
March 30, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
March 21, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
February 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
February 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Research Finds COVID Pandemic Worsened Health Equity Gap
February 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
January 18, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Statement Following New York Jury Ruling in Opioids Trial
December 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.